Press release
Carcinoembryonic Antigen (CEA) Market: Industry Survey and Industry Outlook 2023 by Credence Research
The latest market report published by Credence Research, Inc. “Global Carcinoembryonic Antigen (CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023,” the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.Market Insights
According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few factors that assist the overall market growth are growing healthcare expenditure which is boosting the need for efficient diagnostic procedure for cancer and influencing the usage of combination biomarkers.
Browse the full report Carcinoembryonic Antigen (CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023 at http://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market
The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. In base year 2015, colorectal cancer dominated the overall market in terms of revenue. The key factors responsible for growth of CEA market are increase in number of population consuming alcohol, sedentary lifestyle, and high intake of saturated fats in all age groups. Moreover, rising preference for CEA test in cancer diagnosis and management is expected to assist its market growth in the near future.
In base year 2015, North America was observed as the largest CEA market due to high public awareness related to early cancer diagnosis, rising preference for minimally invasive cancer diagnosis tests and sophisticated health care facilities for cancer management. Incessant technological developments followed by new discoveries of specific antigens and biomarkers are anticipated to boost the growth of CEA market testing. The key factors assisting the growth of CEA market comprises aging population, highly accessible technologically advanced healthcare facilities, successful governmental and non-governmental initiatives, and demand for precise diagnostic procedures.
Market Competition Assessment:
The carcinoembryonic antigen (CEA) market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Quest Diagnostics, F. Hoffman LA Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.
Key Market Movements:
• Rising prevalence of cancer is expected to drive the CEA tests market in the near future
• Increasing demand for minimally invasive diagnosis methods for cancer
• Growing healthcare expenditure in developing countries is assisting the growth of CEA tests
• The regulatory framework for approval process has always been the most critical restraining factor in the cancer diagnosis
• According to NICE, the specificity in detecting diseases is almost between 30-80% during CEA test for the diagnosis of early colorectal cancer. This test is much more useful in detecting prognosis other than early diagnostic phase, where the specificity is expected to be 65% of detecting diseases
Request Sample: http://www.credenceresearch.com/sample-request/58091
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
105 N 1st ST #429, SAN JOSE,
CA 95103, United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Carcinoembryonic Antigen (CEA) Market: Industry Survey and Industry Outlook 2023 by Credence Research here
News-ID: 421842 • Views: …
More Releases from credence research

Pharmacy Market Size, Growth | Industry Report, 2023-2032
The latest market report published by Credence Research, Inc. The demand for the US Retail Pharmacy Market, valued at USD 569.79 Billion in 2023, is projected to soar to USD 948.80 Billion by 2032, marking a robust compound annual growth rate (CAGR) of 5.76% during the period from 2024 to 2032.
The US retail pharmacy market stands as a cornerstone of the nation's healthcare infrastructure, serving as the frontline for patient…

Medical Headgears Market is Expected to Reach USD 2,184.62 million by 2032 | Cre …
The Medical Headgears Market is poised for substantial growth, with a market value of USD 1,247.86 million in 2024 projected to surge to USD 2,184.62 million by 2032, representing a robust compound annual growth rate (CAGR) of 6.36%.
In the realm of healthcare, innovation is key, and this holds true for the field of medical headgears. These devices play a crucial role in various medical applications, from orthodontics to craniofacial…

Quality Management Software Market Size, Share, Analysis, Growth & Forecast 2030
The latest market report published by Credence Research, Inc. The global demand for Quality Management Software market was valued at USD 9654.8 Million in 2023 and is expected to reach USD 24697.3 Million in 2032, growing at a CAGR of 11.00% between 2024 and 2032.
In today's fast-paced and highly competitive business landscape, ensuring the highest level of product or service quality is paramount. Quality management is not just a goal…

Commercial Drone Market Size, Growth to Reach USD 56756.3 Million by 2030 | Cred …
The latest market report published by Credence Research, Inc. The global demand for Commercial Drone was valued at USD 19482.5 Million in 2022 and is expected to reach USD 56756.3 Million in 2030, growing at a CAGR of 14.30% between 2023 and 2030.
In recent years, the commercial drone market has experienced exponential growth, revolutionizing industries and opening up new possibilities for businesses across the globe. From agriculture and construction to…
More Releases for CEA
CEA ELISA Kits Market Outlook and Future Projections for 2030
The cea elisa kits market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Carcinoembryonic Antigen (CEA) Market Size, Share | Industry Report 2026
The global Carcinoembryonic Antigen (CEA) Market was valued at $5.3 Billion in 2018 and is forecast to grow at a modest 6.1 % CAGR between 2018 and 2026, culminating in 2026 global sales of $ 9.2 Billion.
Carcinoembryonic AntigenTest is a blood test which identifies the diagnose and manage certain cancer disease like rectum and large intestine. Basically, it is used to check how well treatment is working in certain…
Carcinoembryonic Antigen (CEA) Market Investment Research Report 2017 – 2027
Carcinoembryonic antigen (CEA) is normally found in embryonic entodermal epithelium. Carcinoembryonic antigen is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. Carcinoembryonic antigen is also present in the mucosal cells of the colorectum, gastrointestinal cells, and small amounts are present in the blood. Carcinoembryonic antigen is produced by the gastrointestinal tissues during the development of fetal. CEA is not…
Carcinoembryonic Antigen (CEA) Market foreseen to grow exponentially over 2027
Carcinoembryonic antigen (CEA) is normally found in embryonic entodermal epithelium. Carcinoembryonic antigen is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. Carcinoembryonic antigen is also present in the mucosal cells of the colorectum, gastrointestinal cells, and small amounts are present in the blood. Carcinoembryonic antigen is produced by the gastrointestinal tissues during the development of fetal. CEA is not…
Carcinoembryonic Antigen (CEA) Market to hit $2.7bn by 2023
Carcinoembryonic Antigen (CEA) Market size is driven by increasing incidence rate for cancer disease especially colorectal cancer is one of the important factor contributing to the growth. Global Carcinoembryonic Antigen Market is set to register profitable growth in the near future and surpass USD 2.8 billion by 2023.
This growth is attributed to factors including consistent technology advancements, development of novel biomarkers and growing prevalence of cancer. Global Market Insights,…
CEA Antibodies Market Outlook And Research Survey To 2023
CEA stands for carcinoembryonic antigen, is a protein that is usually produced in developing fetus and disappears or is absent in adults. Production of abnormal amount of CEA protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein that is non-cancerous in…